酪氨酸激酶膜受体在膀胱癌中的作用机制及临床应用  

Membrane receptor tyrosine kinases in bladder cancer:mechanisms and clinical application

作　　者：郭昭群 王雍博 潘锦锋 王科洁 叶沙舟 贾晓龙 马琪 GUO Zhaoqun;WANG Yongbo;PAN Jinfeng;WANG Kejie;YE Shazhou;JIA Xiaolong;MA Qi(School of Medicine,Ningbo University,Ningbo 315211,China;Cixi Biomedical Research Institute,Wenzhou Medical University,Ningbo 315300,China;Department of Urology,the First Affiliated Hospital of Ningbo University,Ningbo 315699,China;Comprehensive Genitourinary Cancer Center,the First Affiliated Hospital of Ningbo University,Ningbo 315000,China)

机构地区：[1]宁波大学医学部,宁波315211 [2]温州医科大学慈溪生物医药研究院,宁波315300 [3]宁波大学附属第一医院泌尿外科,宁波315699 [4]宁波大学附属第一医院泌尿肿瘤综合诊治中心,宁波315000

出　　处：《生命的化学》2025年第3期450-460,共11页Chemistry of Life

基　　金：宁波市泌尿系疾病临床医学研究中心项目(2019A21001);宁波市医疗卫生高端团队重大攻坚项目(2022020203);宁波市医学科技计划项目(2021Y06);宁波市自然科学基金项目(20221JCGY010080)。

摘　　要：膀胱癌(bladder cancer,BCa)是泌尿系统常见的恶性肿瘤,发病率在全球范围内逐年上升。近年来,尽管BCa的治疗取得了多项进展,但发病率及病死率仍然较高。酪氨酸激酶膜受体(membrane receptors tyrosine kinase,mRTKs)是目前BCa治疗中备受瞩目的潜力靶点,针对这些受体的靶向疗法正在逐步走向临床。本文综述了BCa中常见的mRTKs的结构、功能及相应细胞内信号传导,并介绍了靶向mRTKs在BCa基础研究与临床研究中的进展,探讨了靶向mRTKs药物在BCa治疗中的潜力。Bladder cancer(BCa)is a common malignant in the urinary system,and its incidence is increasing globally.In recent years,although significant advances have been made in the treatment of BCa,the incidence and case fatality rate remain high.Membrane receptors tyrosine kinase(mRTKs)have emerged as promising targets for BCa treatment.With understanding the role of m RTKs in the BCa,more and more targeted therapies against these mRTKs have been investigated for clinical applications.This review summarizes the role of most common mRTKs in BCa.Their structure,biological function,and signal transduction are also discussed.Furthermore,basic and clinical studies involved in these mRTKs in BCa treatment are introduced and further directions are also discussed.

关 键 词：膀胱癌 酪氨酸激酶膜受体 靶向疗法 

分 类 号：R737.14[医药卫生—肿瘤]